http://buff.ly/2d0OTaB: On 12 June 2016 the 1-year results of the REVISE-Diabesity research study of Endobarrier treatment, including an assessment of the impact on 10-year cardiovascular risk, were presented at the 76th Scientific Sessions of the American Diabetes Association in New Orleans, USA, by the study’s Chief Investigator, Dr Bob Ryder. The headline results were that in the Endobarrier with liraglutide group, mean weight fell by 12.3kg from 112.7kg (BMI 40.3) to 100.4 kg (BMI 35.8) and alongside this mean HbA1c came down from 9.6% (81.4 mmol/mol) to 7.5% (58.5 mmol/mol). Using the UKPDS risk engine it was estimated from the results that out of such 100 patients treated in this way, 22 coronary heart disease events or stroke would be prevented and 18 lives would be saved over the next 10 years. Because of the success of the study, BBC Midlands Today ran this news item on Endobarrier which can be viewed at https://youtu.be/xRcnMBOdb58 .
Dr Piya SenGupta
ABCD Research Fellow
